Pyrazol-phenol Compounds for BRG1-Deficient Cancer Treatment
Solution Overview
Problem
Current compounds for treating cancers, particularly those targeting BRG1-deficient cancers, suffer from insufficient activity and limited druggability, especially for compounds of the 2-(1H-pyrazol-3-yl)phenol type, which restricts their application scope.
Innovation Solution
Development of specific compounds represented by Formula (II) and its derivatives, including pharmaceutically acceptable salts, stereoisomers, and solvates, which are synthesized through detailed reaction routes, offering broader substituent options and improved druggability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If compounds of the 2-(1H-pyrazol-3-yl)phenol type with only alkyl substituent groups are used, then the compound structure is simple, but the application scope is greatly limited
Solution Approach 1:
The patent applies local quality by introducing different substituent groups (halogen, alkoxy, alkylthio, carboxyl, hydroxyl, amino, etc.) at specific positions (R2, R8, R16-R20) of the pyrazole ring and phenol group. This allows different regions of the molecule to have different chemical properties, enabling the compound to interact with various biological targets and significantly expanding the application scope while maintaining a relatively simple core structure.
Solution Approach 2:
The patent creates a universal compound framework that can serve multiple therapeutic purposes. By allowing various substituent groups at different positions, a single core structure can be adapted to treat different types of cancers (BRG1-deficient cancers, NSCLCs, etc.) and target different biological pathways, achieving multi-functionality without requiring completely different molecular structures for each application.
2Reliability
If existing compounds for treating BRG1-deficient cancers are used, then the treatment target is specific, but the activity is insufficient and druggability is poor
Solution Approach 1:
The patent systematically varies key molecular parameters including substituent types (halogen, alkoxy, carboxyl, etc.), substituent positions (R2, R8, R16-R20), and molecular weight ranges to optimize the compound's interaction with the BRM protein. This parameter optimization enhances both the specificity for the BRM target and the therapeutic activity, resulting in compounds with improved druggability and potency against BRG1-deficient cancers.
Data Source
AI summary
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, ether, ester, prodrug and solvate thereof. The compound can be used for preventing and/or treating cancers.



